Pharma Focus Asia
Eppendorf Bioprocess Solutions

Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

05

Jun 2023

BiondVax Pharmaceuticals Signs Exclusive Licence Agreement to Develop and Commercialise Novel Anti-IL-17 Antibody

BiondVax Pharmaceuticals announced that it has signed an exclusive worldwide licence agreement to develop and commercialise VHH antibodies NanoAbs targeting Interleukin IL as treatments for various indications starting with psoriasis and psoriatic arthritis This collaboration involves the Max Planck...

05

Jun 2023

Daiichi Sankyo and American Regent Announce Approval of INJECTAFER® A

Daiichi Sankyo and American Regent have jointly announced the approval of INJECTAFER ferric carboxymaltose injection by the US Food and Drug Administration FDA

05

Jun 2023

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Collaborate to Develop and Commercialise NRX-101

Lotus Pharmaceuticals Alvogen and NRx Pharmaceuticals have entered into a global collaboration agreement

03

Jun 2023

Innovent Receives China's National Medical Products Administration Approval for Olverembatinib

Innovent Biologics announced that the Centre for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has awarded Breakthrough Therapy Designation BTD for olverembatinib

02

Jun 2023

Astrea Bioseparations joins Biotage, enabling groundbreaking chromatography solutions

Biotage has completed the acquisition of Astrea Bioseparations a highgrowth chromatography solutions provider from Gamma Biosciences a life sciences tools platform created by KKR

01

Jun 2023

Bayer Announces Exclusive Licence Agreement with Cedilla Therapeutics

Bayer and Cedilla Therapeutics have recently entered into an exclusive licence agreement to collaborate on the development and commercialisation of Cedilla Therapeutics CyclinECDK complex inhibitors

press releasesRead more...

06

Jun 2023

Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)

Vaxxas a clinicalstage biotechnology company commercializing a novel vaccination platform today announced positive interim results from a Phase I human clinical trial with the first needlefree COVID vaccine candidate delivered using Vaxxas proprietary highdensity microarray patch HDMAP technology

06

Jun 2023

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Ractigen Therapeutics a biopharmaceutical company focused on the discovery development and commercialization of novel oligonucleotide therapeutics today announced the dosing of its first patient in the Companys First in Human FIH clinical trial for ALS patients with SOD mutation RAG is a siRNA drug...

06

Jun 2023

Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada upon Termination of License Agreement with Neurogastrx

Daewoong Pharmaceutical CEO Jeon Sengho Lee Changjae today announced that it and Neurogastrx have agreed to terminate the June license agreement which granted Neurogastrx exclusive right to develop and commercialize Fexuprazan with respect to the US and Canada market

05

Jun 2023

Dr. Reddy’s successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumab

Dr Reddys Laboratories Ltd BSE NSE DRREDDY NYSE RDY NSEIFSC DRREDDY hereafter referred to as Dr Reddys a global pharmaceutical company announced that its tocilizumab biosimilar candidate DRLTC successfully met its primary and secondary endpoints in a Phase I study This Phase I study used an intrave...

05

Jun 2023

Chimeric announces launch of new phase 1b glioblastoma clinical trial

Chimeric Therapeutics ASXCHM Chimeric or the Company the only clinical stage cell therapy company on the ASX is pleased to announce activation of a Phase B clinical trial in patients with recurrent and or progressive glioblastoma multiforme GBM to assess the safety and efficacy of CHM the companys...

03

Jun 2023

Pharmaessentia Selects Pint-pharma As Commercial Partner For Besremi® (Ropeginterferon Alfa-2b-njft) In Latin America

PharmaEssentia Corporation TPEx a leading fully integrated biopharmaceutical company in Taiwan today announced that it has entered into an exclusive license agreement with PintPharma GmbH for the registration and promotion of BESREMi ropeginterferon alfabnjft for the treatment of polycythemia vera P...

06 - 07

Jun 2023

06 - 07

Jun 2023

Discovery Europe

Berlin, Germany

06 - 07

Jun 2023

08 - 09

Jun 2023

RNA Therapeutics

Boston, USA

12 - 13

Jun 2023

PHARMACEUTICAL MANUFACTURING

Geneva, Switzerland

Testing The WorldCelebrating 70 Years of Nalgene
Bora Pharmaceutical - A robust approach to analytical testing is essential
Selangor International Expo MEDIC 2023
TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applications
Medical Fair Thailand 2023
ThermoFisher Scientific - NEW Mobile App
CPHI & PMEC China 2023
THERMOFISHER SEA
Upm Raflatac
TFS
TFS
TFS
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology

TOP ARTICLES

  • 3

    Approach for Producing Pharmaceuticals in Layer By Layer Fashion: Additive Manufacturing

    Lakshmi usha Ayalasomayajula

    Assistant Professor, Department of Pharmaceutical Technology, M.R. College of Pharmacy

    Earle Radha Rani

    Department of Pharmaceutics, Maharajah's College of Pharmacy

    AVS Ksheera Bhavani

    Department of Pharmaceutics, Sri Venkateswara College Of Pharmacy

    Kishore Pathivada

    Department of Pharmaceutics, Maharajah's College of Pharmacy

KNOWLEDGE BANK

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia

    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshooting and technical training for downstream processes Chan holds a degree in Chemical Engineering from the National University of Singapore
  • Articles

    Advanced Nanobots for ‘Programmed’ Biomedical Applications

    The idea of nanobots that could perform programmed tasks at targeted sites by traveling through biological fluids is no more in science fiction now Recent development in the field of nanotechnology provides the scope of designing miniaturised tiny nanobots which are even smaller than the dimension of biological cells

EDITORIAL SECTION